Related Experiment Video
Updated: Nov 29, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Cerebrovascular disease promotes tau pathology in Alzheimer's disease
Krystal K Laing1, Sabrina Simoes1, Gloria P Baena-Caldas2
1Taub Institute for Research on Alzheimer's Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Abstract:
Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer's disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer's pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer's disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer's Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer's disease (n = 97), mild cognitive impairment (n = 186) or cognitively normal control (n = 108). We tested the relationship between plasma tau concentration and white matter hyperintensity volume across diagnostic groups. We also examined the extent to which white matter hyperintensity volume, plasma tau, amyloid positivity status and the interaction between white matter hyperintensities and plasma tau correctly classifies diagnostic category. Increased white matter hyperintensity volume was associated with higher plasma tau concentration, particularly among those diagnosed clinically with Alzheimer's disease. Presence of brain amyloid and the interaction between plasma tau and white matter hyperintensity volume distinguished Alzheimer's disease and mild cognitive impairment participants from controls with 77.6% and 63.3% accuracy, respectively. In 63 Alzheimer's Disease Neuroimaging Initiative participants who came to autopsy (82.33 ± 7.18 age at death), we found that higher degrees of arteriosclerosis were associated with higher Braak staging, indicating a positive relationship between cerebrovascular disease and neurofibrillary pathology. In a transient middle cerebral artery occlusion mouse model, aged mice that received transient middle cerebral artery occlusion, but not sham surgery, had increased plasma and cerebrospinal fluid tau concentrations, induced myelin loss, and hyperphosphorylated tau pathology in the ipsilateral hippocampus and cerebral hemisphere. These findings demonstrate a relationship between cerebrovascular disease, operationalized as white matter hyperintensities, and tau levels, indexed in the plasma, suggesting that hypoperfusive injury promotes tau pathology. This potential causal association is supported by the demonstration that transient cerebral artery occlusion induces white matter damage, increases biofluidic markers of tau, and promotes cerebral tau hyperphosphorylation in older-adult mice.
Insights
Small vessel cerebrovascular disease, seen as white matter hyperintensities, is linked to higher plasma tau levels in Alzheimer's disease (AD) patients. This suggests hypoperfusive injury promotes tau pathology, a key AD hallmark.
Area of Science:
- Neurology
- Neuroscience
- Biomarkers
Background:
- Small vessel cerebrovascular disease, indicated by white matter hyperintensities (WMH) on MRI, is common in Alzheimer's disease (AD).
- The precise relationship between cerebrovascular disease and AD pathology, specifically tau, remains incompletely understood.
- Investigating this link may reveal new diagnostic and therapeutic targets for AD.
Purpose of the Study:
- To examine the association between white matter hyperintensities (WMH) and plasma tau levels in individuals with Alzheimer's disease (AD).
- To determine if WMH and plasma tau interact to predict AD diagnosis.
- To investigate the causal link between cerebrovascular injury and tau pathology using a mouse model.
Main Methods:
- Cross-sectional analysis of 391 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with WMH, plasma tau, and CSF beta-amyloid measurements.
- Classification into Alzheimer's disease, mild cognitive impairment, and cognitively normal groups.
- Validation in a mouse model of transient middle cerebral artery occlusion (tMCAO) to assess tau biomarkers and pathology post-ischemic injury.
- Post-mortem analysis of brain tissue from 63 ADNI participants to correlate arteriosclerosis with Braak staging.
Main Results:
- Increased WMH volume correlated with higher plasma tau concentrations, especially in clinically diagnosed Alzheimer's disease patients.
- The combination of brain amyloid status and the interaction between plasma tau and WMH volume accurately classified AD and mild cognitive impairment from controls (77.6% and 63.3% accuracy, respectively).
- In mice, tMCAO induced tau pathology, myelin loss, and elevated tau biomarkers, supporting a causal link between ischemic injury and tau accumulation.
Conclusions:
- Cerebrovascular disease, evidenced by white matter hyperintensities, is associated with elevated plasma tau levels.
- Hypoperfusive injury resulting from cerebrovascular disease appears to promote tau pathology, contributing to Alzheimer's disease progression.
- These findings highlight the interplay between vascular health and neurodegeneration in Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....

